Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    GBP4m

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Halyk Bank

    MCap

    USD6,872m

    Last close

    USD24.70

    ▲ 0.65 (2.70%)

    Centaur Media

    MCap

    GBP41m

    Last close

    GBP0.27

    ▲ −1.60 (−5.59%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Immix Biopharma (NASDAQ: IMMX)

Last close As at 29/03/2025

USD1.70

▲ −0.03 (−1.73%)

Market capitalisation

USD48m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Flash

Immix Biopharma — NXC-201 receives FDA RMAT designation

Healthcare | Outlook

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Healthcare | Comment

Immix (NASDAQ: IMMX) presents positive data in ALA

Healthcare | Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion
Scientist using protective robber gloves for handling substances and experiments
Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Flash note

Healthcare

Immix Biopharma — Increased legroom following common-only raise
Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — Encouraging stream of ALA data newsflow
Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — KOL event: Glimmer of hope for ALA patients

Flash note

Healthcare

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Update

Healthcare

Immix Biopharma — A quarter of progress for both lead assets

Update

Healthcare

Immix Biopharma — A step toward delivering a practical CAR-T option

Flash note

Healthcare

Immix Biopharma — NXC-201 gains orphan drug designation in ALA

Flash note

Healthcare

Immix Biopharma — NXC-201 gains Orphan Drug designation in MM

Update

Healthcare

Immix Biopharma — Progressing as expected on all fronts
Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — IMX-110 interim results in colorectal cancer

Flash note

Healthcare

Immix Biopharma — ATM completion may extend runway into H224

Update

Healthcare

Immix Biopharma — A quarter focusing on a CAR-T strategy

Flash note

Healthcare

Immix Biopharma — CAR-T treatment continues to show promise
Cancer cells low poly blue

Update

Healthcare

Immix Biopharma — Pipeline momentum continues in FY23
Scientist using protective robber gloves for handling substances and experiments

Flash note

Healthcare

Immix Biopharma — Positive data from CAR-T treatment continues
Scientist using protective robber gloves for handling substances and experiments

Update

Healthcare

Immix Biopharma — Expanding portfolio into CAR-T cell therapy
Scientist using protective robber gloves for handling substances and experiments

Flash note

Healthcare

Immix Biopharma — Encouraging progress on multiple fronts

Flash note

Healthcare

Immix Biopharma — Potential upside with expansion into CAR-T

Update

Healthcare

Immix Biopharma — IMX-110 clinical expansion on the horizon

edison tv

Healthcare

Immix Biopharma – executive interview

Initiation

Immix Biopharma — Fresh faces with a unique tissue-targeting therapy